Skip to main content
Signal8
Launch Terminal

Sight Sciences, Inc. (SGHT)

Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Sight Sciences, Inc. logo

Sight Sciences, Inc.

NASDAQ:SGHTHealthcare
-2.61%$9.32
AH$9.32+0.00%vs close
Mkt Cap$513.42M
Float36.87M
O/S55.09M
Vol
$ Vol
RVOL
Inst Own37.1%
Earnings
Dilution
Sight Sciences, Inc. logoNASDAQ:SGHT$9.32-2.61%
Phase Distribution
19 lead-sponsored trials·2 active·10 completed
Phase 41
Not applicable18
(1 more as collaborator)
Status Overview
Active, not recruiting2
Completed10
Stopped6
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Terminated

    A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

    Latanoprost plus adjunctive glaucoma medication

    Primary Open Angle Glaucoma

    Enrollment
    2
    Start
    Aug 2024
    Primary Completion
    Jan 2025
    Completion
    Jan 2025
    NCT06407973
  • Not applicable
    Terminated

    Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

    VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT)

    Open-Angle Glaucoma

    Enrollment
    29
    Start
    Jan 2017
    Primary Completion
    Jan 2019
    Completion
    Jan 2019
    NCT02928289
  • Not applicable
    Completed

    A Pilot Study of the TearCare System in Adults With Dry Eye Disease

    TearCare, Warm Compress

    Dry Eye

    Enrollment
    24
    Start
    Jan 2017
    Primary Completion
    Feb 2017
    Completion
    Mar 2018
    NCT03006978
  • Not applicable
    Terminated

    Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye Disease

    TearCare, Warm Compress and Lid Massage

    Dry Eye Syndromes

    Enrollment
    14
    Start
    Apr 2018
    Primary Completion
    Dec 2018
    Completion
    Dec 2018
    NCT03502447
  • Not applicable
    Completed

    Study of the TearCare System in Dry Eye Disease

    TearCare

    Dry Eye

    Enrollment
    29
    Start
    Jul 2018
    Primary Completion
    Oct 2018
    Completion
    Nov 2018
    NCT03588624
  • Observational
    Completed

    Analytical and Clinical Performance Testing Plan

    Hematology Analyzer - OLO, Hematology Analyzer - Predicate

    Hematology, Hematologic Test

    Enrollment
    679
    Start
    Jun 2018
    Primary Completion
    Mar 2019
    Completion
    Aug 2019
    NCT03595501
  • Not applicable
    Completed

    Pilot Study of TearCare System - Long-Term Extension

    TearCare

    Dry Eye Syndromes

    Enrollment
    12
    Start
    Dec 2018
    Primary Completion
    May 2019
    Completion
    May 2019
    NCT03804502
  • Not applicable
    Completed

    TearCare System to Treat Dry Eye Disease

    TearCare, LipiFlow

    Dry Eye, Meibomian Gland Dysfunction

    Enrollment
    235
    Start
    Mar 2019
    Primary Completion
    Feb 2020
    Completion
    Dec 2020
    NCT03857919
  • Not applicable
    Completed

    Study of OMNI System in OAG (GEMINI)

    Transluminal viscoelastic delivery and trabeculotomy

    Open Angle Glaucoma

    Enrollment
    209
    Start
    Mar 2019
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT03861169
  • Not applicable
    Terminated

    A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma

    OMNI® Surgical System

    Glaucoma, Open-Angle

    Enrollment
    78
    Start
    Jun 2020
    Primary Completion
    Mar 2021
    Completion
    Mar 2021
    NCT04465630
  • Not applicable
    Terminated

    A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

    OMNI® Surgical System, iStent inject

    Glaucoma, Open-Angle

    Enrollment
    1
    Start
    Nov 2020
    Primary Completion
    Jan 2021
    Completion
    Jan 2021
    NCT04616573
  • Observational
    Unknown status

    Performance Evaluation Study

    Fingerstick blood draw

    Hematology

    Enrollment
    50
    Start
    Nov 2020est.
    Primary Completion
    Dec 2020est.
    Completion
    Dec 2020est.
    NCT04618848
  • Not applicable
    Terminated

    Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)

    Canaloplasty and trabeculotomy with the OMNI system., iStent inject

    Glaucoma, Open-Angle

    Enrollment
    10
    Start
    Jan 2022
    Primary Completion
    Nov 2022
    Completion
    Nov 2022
    NCT04658095
  • Not applicable
    Completed

    Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

    Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion

    Dry Eye, Meibomian Gland Dysfunction

    Enrollment
    345
    Start
    Apr 2021
    Primary Completion
    Sep 2024
    Completion
    Sep 2024
    NCT04795752
  • Observational
    Completed

    An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)

    OMNI® Surgical System

    Glaucoma, Open-Angle

    Enrollment
    28
    Start
    Jul 2021
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT04872348
  • Observational
    Completed

    A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System

    OMNI® Surgical System

    Glaucoma, Open-Angle

    Enrollment
    70
    Start
    Sep 2021
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT05044793
  • Not applicable
    Active, not recruiting

    A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)

    Helix Surgical System

    Primary Open Angle Glaucoma, Cataract

    Enrollment
    25
    Start
    May 2025
    Primary Completion
    Sep 2026est.
    Completion
    Sep 2026est.
    NCT06948773
  • Not applicable
    Active, not recruiting

    OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma

    OMNI 3.0 Surgical System

    Primary Open Angle Glaucoma

    Enrollment
    25
    Start
    Oct 2025
    Primary Completion
    Dec 2026est.
    Completion
    Aug 2027est.
    NCT06991270
  • Not applicable
    Completed

    TearCare MGX™ System With and Without Warming Hold

    localized heat therapy

    Meibomian Gland Dysfunction (Disorder)

    Enrollment
    21
    Start
    Mar 2026
    Primary Completion
    May 2026
    Completion
    May 2026
    NCT07365735
Search ClinicalTrials.gov for “Sight Sciences”